Sign in

    Chad Yahn • Maxim Group

    Chad Yahn is an Equity Research Associate specializing in the biotechnology sector at Maxim Group LLC, where he supports coverage of innovative biotech firms and emerging industry leaders. He is involved in detailed analysis and investment research for companies across the biotech landscape, leveraging a strong background in both finance and biotechnology. Chad began his career with a solid academic foundation and has held analytical roles within Maxim Group, contributing to actionable investment research and sector outlooks since joining the firm. He maintains professional credentials pertinent to securities analysis, with expertise spanning equity research and financial modeling for health sciences.

    Chad Yahn's questions to RenovoRx Inc (RNXT) leadership

    Chad Yahn's questions to RenovoRx Inc (RNXT) leadership • Q2 2025

    Question

    Chad Yahn, on behalf of Jason McCarthy from Maxim Group, asked if RenovoRx has engaged with the FDA regarding a potential accelerated approval pathway for its therapy. He also asked how the 16-month median overall survival from the first interim analysis compares to outcomes from similar trials.

    Answer

    Shaun Bagai, CEO & Director, responded that the company plans to engage with the FDA about a potential accelerated approval pathway as they get closer to final data and prepare for a potential New Drug Application (NDA). He contextualized the clinical data by explaining that the control arm's survival rate fits squarely within the 14-18 month range seen in contemporary trials for locally advanced pancreatic cancer, such as Novocure's PANOVA-3 trial, suggesting the bar for showing a meaningful clinical benefit is well-defined and achievable.

    Ask Fintool Equity Research AI

    Chad Yahn's questions to Fennec Pharmaceuticals Inc (FENC) leadership

    Chad Yahn's questions to Fennec Pharmaceuticals Inc (FENC) leadership • Q2 2025

    Question

    Chad Yahn, on behalf of Jason McCarthy from Maxim Group, requested clarification on how an ENCOTA PQI differs from NCCN guidelines and asked about the allocation of marketing resources between the pediatric and the larger AYA patient populations.

    Answer

    CEO Jeff Hackman described the ENCOTA PQI as a more granular, peer-reviewed guidance document that provides practical, evidence-based recommendations for oncology care teams to standardize care and optimize treatment, differing from the broader NCCN guidelines. He also stated that while the AYA market is the larger opportunity, the commercial and medical teams are instructed to address both pediatric and AYA needs when visiting institutions. CFO Robert Andrade added that relationships in each market have created opportunities in the other, highlighting a synergistic approach.

    Ask Fintool Equity Research AI